Changes of Bone-Related Minerals during Denosumab Administration in Post-Menopausal Osteoporotic Patients
AbstractObjectives: This retrospective study included 21 patients with primary osteoporosis who were treated with the anti-resorption drug, denosumab. To date, there has been no detailed report on the changes of bone-related minerals after anti-resorption drug therapy. Methods: Twenty-one post-menopausal females were retrospectively enrolled. Serum zinc (Zn), magnesium (Mg), iron (Fe), copper (Cu), grip strength, and estimated glomerular filtration rate (eGFR) were examined at one week and 1, 2, 4, 6, 8, 10, and 12 months. Lumbar spine (L1-4) bone mineral density (L-BMD) and bilateral total hip BMD (H-BMD) were examined before and at 4, 8, and 12 months after treatment commencement. Results: Serum Zn tended to decrease at one week and one month, and tended to increase during 10 to 12 months. Serum Cu maintained during zero to eight months, then decreased at 10 and 12 months. Serum Fe gradually increased after four months. Serum Mg sharply increased at one week, then decreased further. Grip strength increased for two months, then slightly decreased and maintained 4 to 12 months. eGFR almost maintained for zero to eight months, then slightly decreased thereafter. L-BMD values significantly increased at eight (5.8%) (p < 0.01) and 12 months (9.8%) (p < 0.01). H-BMD increased during the period (at 12 months: 3.7%). Conclusions: These results suggest that at later phases of denosumab therapy, Zn and Fe tended to increase while Mg tended to decrease, all of which are important for bone metabolism. Thus, denosumab might improve Zn and Fe metabolism, and thereby likely increase BMD. Since denosumab may not improve Mg, it is better to obtain Mg supplementation during the therapy. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Suzuki, T.; Nakamura, Y.; Kato, H. Changes of Bone-Related Minerals during Denosumab Administration in Post-Menopausal Osteoporotic Patients. Nutrients 2017, 9, 871.
Suzuki T, Nakamura Y, Kato H. Changes of Bone-Related Minerals during Denosumab Administration in Post-Menopausal Osteoporotic Patients. Nutrients. 2017; 9(8):871.Chicago/Turabian Style
Suzuki, Takako; Nakamura, Yukio; Kato, Hiroyuki. 2017. "Changes of Bone-Related Minerals during Denosumab Administration in Post-Menopausal Osteoporotic Patients." Nutrients 9, no. 8: 871.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.